KMICB - Gastro-intestinal system
Kent and Medway Guidance
K&M Inflammatory Bowel Disease (Adults) HCD Pathway
K&M PRGC PR 2024-10: Dose escalation of subcutaneous infliximab for inflammatory bowel disease (IBD)
PRGC 2022-25: Dual biological therapy for inflammatory bowel disease (IBD) in adults
K&M ICB Position Statement – GI Anti-spasmodics: Dicycloverine and Propantheline prescribing not supported
K&M Stoma Accessories Formulary
K&M ICB Position Statement - Proton Pump Inhibitor (PPI) Oral Suspension for Adults in Primary Care
K&M ICB Position Statement - Omeprazole Oral Suspension for Paediatrics in Primary Care
K&M ICB Gluten-Free Product Prescribing – FAQs
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary